Literature DB >> 10890318

HCV genotypes--role in pathogenesis of disease and response to therapy.

G Webster1, E Barnes, D Brown, G Dusheiko.   

Abstract

Hepatitis C virus (HCV) shows considerable variation in its genomic structure, allowing classification into six main genotypes. Epidemiological studies have shown marked differences in genotype distribution by geographical region, and between patient groups. Improved understanding of the rate of nucleotide sequence mutation in HCV has allowed the approximate time of divergence of major genotypes to be estimated, and the origin and spread of the present epidemic of hepatitis C to be better defined. Improved methods of genotype definition over the last few years have enabled the importance of genotype in the progression of HCV-related disease and response to anti-viral therapy to be studied. Present data strongly indicates that HCV genotype is an important determinant of response to treatment, but the effect of genotype on disease progression has been harder to clarify. This is largely due to the absence of model systems of HCV infection, the epidemiological differences in patient groups infected with the different genotypes, and the lack of good prospective longitudinal clinical data. As a result of advances in methodology, and recent results of large clinical trials of combination therapy, a knowledge of HCV genotype is now central to the clinician in the management of patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890318     DOI: 10.1053/bega.1999.0072

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  7 in total

1.  Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C.

Authors:  Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

Review 2.  Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

Authors:  E B Melian; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe.

Authors:  Nyasha Chin'ombe; Evans Chavhunduka; Hilda T Matarira
Journal:  Infect Agent Cancer       Date:  2009-10-08       Impact factor: 2.965

6.  Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil.

Authors:  Rosa Maria S Gonzaga; Itatiana F Rodart; Mitermayer Galvão Reis; Cícero Eduardo Ramalho Neto; Denise Wanderlei Silva
Journal:  Braz J Microbiol       Date:  2008-12-01       Impact factor: 2.476

7.  Coinfection with Hepatitis C and HIV Is a Risk Factor for Poor Outcomes After Total Knee Arthroplasty.

Authors:  Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan M Vigdorchik; Richard Iorio; Ran Schwarzkopf
Journal:  JB JS Open Access       Date:  2017-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.